Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy

BACKGROUND: Cabozantinib is a potent, multitarget inhibitor of MET and vascular endothelial growth factor receptor 2 (VEGFR2). This open-label, phase II trial evaluated cabozantinib in patients with recurrent or progressive glioblastoma (GBM). METHODS: Patients were initially enrolled to a starting...

Descripción completa

Detalles Bibliográficos
Autores principales: Cloughesy, Timothy F, Drappatz, Jan, de Groot, John, Prados, Michael D, Reardon, David A, Schiff, David, Chamberlain, Marc, Mikkelsen, Tom, Desjardins, Annick, Ping, Jerry, Holland, Jaymes, Weitzman, Ron, Wen, Patrick Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777491/
https://www.ncbi.nlm.nih.gov/pubmed/29036345
http://dx.doi.org/10.1093/neuonc/nox151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777491/
https://www.ncbi.nlm.nih.gov/pubmed/29036345
http://dx.doi.org/10.1093/neuonc/nox151

Ejemplares similares